The system aims to address underlying chronic cough and issues with mucus production and clearance in chronic bronchitis.

Threat actors are systematically hunting for misconfigured proxy servers that could provide access to commercial large ...

Vanda Pharma announces receipt of US FDA decision letter on Hetlioz sNDA for jet lag disorder: Washington Saturday, January 10, 2026, 13:00 Hrs [IST] Vanda Pharmaceuticals Inc. (V ...

A successful Phase 3 trial and a public offeringof stock boosted prospects for this company to receive approval for an ...

Takeda and Protagonist Therapeutics have submitted a new drug application to the FDA for rusfertide for adults with ...

Shares of Alumis surged after the company said both of its phase three trials of its envudeucitinib drug for moderate-to-severe plaque psoriasis met all primary and secondary endpoints. The stock more ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has received a decision letter from the U.S. Food ...

MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License ...

The main exhibition booth (LVCC, Central Hall, 19227), in collaboration with TMTPOST, emphasized visuals and experiences, ...

OSAKA, Japan & CAMBRIDGE, Mass. & NEWARK, Calif., January 05, 2026--Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) ("Protagonist") announced the submission of a New Drug ...